Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

617
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
617
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

606
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
606
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

602
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

661
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
661
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

423
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Primary prevention of cardiovascular disease in women.

Climacteric : the journal of the International Menopause Society·2024
Same author

Closing the gap: cardiovascular disease in women.

Climacteric : the journal of the International Menopause Society·2024
Same author

Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2016
Same author

Role of new sirolimus self-apposing stent in coronary interventions.

Minerva cardioangiologica·2014
Same author

Targeting transradial approach.

Panminerva medica·2014

Related Experiment Video

Updated: Apr 12, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K

Current controversies in PCI pharmacotherapy.

G Giustino1, R Mehran

  • 1The Zena and Michael A., Wiener Cardiovascular Institute, Icahn School of Medicine at Mount SinaiNew York, NY, USA - roxana.mehran@mountsinai.org.

Minerva Cardioangiologica
|May 9, 2015
PubMed
Summary

Optimizing antithrombotic therapy for coronary artery disease patients undergoing percutaneous coronary intervention (PCI) requires balancing efficacy and bleeding risk. Individualized treatment strategies are crucial for improving outcomes.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K

Related Experiment Videos

Last Updated: Apr 12, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Biology

Background:

  • Coronary artery disease (CAD) and atherothrombosis involve complex interactions of anatomical, cellular, and molecular factors.
  • Revascularization partially addresses ischemic heart disease; pharmacological therapies targeting atherothrombosis are essential for preventing complications.
  • Antithrombotic therapies aim to balance anti-thrombotic efficacy with bleeding risk, a challenge in clinical practice.

Purpose of the Study:

  • To review current debates and controversies in acute and chronic anticoagulant and antiplatelet therapies for patients undergoing PCI.
  • To emphasize the need for individualized pharmacotherapy selection based on ischemic and hemorrhagic risk.
  • To highlight the importance of optimizing antithrombotic strategies in the context of PCI.

Main Methods:

  • Review of current literature on antithrombotic pharmacotherapies.
  • Analysis of the interplay between pharmacological agents, CAD phenotype, and comorbidities.
  • Discussion of individualized risk assessment for PCI pharmacotherapy selection.

Main Results:

  • Optimal antithrombotic therapy presents a complex challenge due to the need to maximize efficacy while minimizing bleeding risk.
  • Patient-specific factors, including clinical phenotype and comorbidities, significantly influence treatment decisions.
  • A shift towards customized patient care is necessary given the availability of diverse pharmacologic agents and diagnostic tools.

Conclusions:

  • Individualized evaluation of ischemic and hemorrhagic risk is paramount for selecting optimal acute and chronic PCI pharmacotherapy.
  • Antithrombotic therapy selection requires careful consideration of potency, duration, and adherence.
  • Effective management of atherothrombosis necessitates a tailored approach to antithrombotic treatment in PCI patients.